Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA
Key facts
- Who runs it
- Ultragenyx Pharmaceutical Inc
- Where
- Columbus, United StatesSee the siteAlso in 2 other countries, 3 sites
- Status
- Enrolling by invitation
- Phase
- Phase 3
- People taking part
- 41 people, planned
- Started
- 28 Sept 2020
- Expected to end
- Aug 2027
- Type of study
- Interventional, 2 groups
- Treatments tested
- No Investigational Product
- Adjuvant Immunomodulatory (IM) Therapy
- Record updated
- 17 July 2026
Who can take part
- Age
- Up to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Participants that have participated in a prior clinical trial in which they received UX111
- Parent(s)/legal guardian(s) of participant willing and able to complete the informed consent process and comply with study procedures and visit schedule
Who cannot take part
- Any other situation or medical condition that precludes the participant from undergoing procedures required in this study
- Planned or current participation in another clinical trial that may confound the safety or efficacy evaluation of UX111 during this study
Where in United States
Also in 2 other countries, 3 sites
- Nationwide Children's HospitalColumbus, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
The main objective of this study is to evaluate the safety/tolerability and efficacy of UX111 (previously known as ABO-102) in participants with Mucopolysaccharidosis IIIA (MPS IIIA).
The 2 groups in the trial
- Cohort AOther group
Participants who have participated in a prior clinical trial involving the administration of UX111 (rebisufligene etisparvovec) and are able to comply with onsite scheduled visits and assessments. Select participants may receive adjuvant IM therapy.
Treatment: No Investigational Product and Adjuvant Immunomodulatory (IM) Therapy
- Cohort BOther group
Participants who have participated in a prior clinical trial involving the administration of UX111 (rebisufligene etisparvovec) and who cannot participate in Cohort A. Participants will partake in a reduced number of assessments, performed either onsite or at home via a combination of telehealth and home healthcare visits.
Treatment: No Investigational Product
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Long-term Follow-up Study of Patients With MPS IIIA From Gene Therapy Clinical Trials Involving the Administration of ABO-102 (scAAV9.U1a.hSGSH)
- Record updated
- 17 July 2026